Breast MRI Screening for the Clinician: Evolution to Current Evidence-Based Practice

R Jared Weinfurtner* and Jennifer Drukteinis

Breast Imaging, Moffitt Cancer Center, United States of America

*Corresponding author: R Jared Weinfurtner, MD, Assistant Professor of Breast Imaging, Moffitt Cancer Center, 10920 N McKinley Dr, Tampa, FL 33647, United States of America, E-mail: robert.weinfurtner@moffitt.org

Abstract

The utility of MRI in the detection of breast cancer has evolved over the last few decades. It is now the most sensitive imaging tool available for the diagnosis of invasive breast cancer. There are drawbacks however, namely increased cost in comparison to screening mammography and decreased specificity. Thus, it is important to tailor the use of breast MRI to specific screening populations in order to maximize the benefit to drawback ratio. In this review, the current evidence for screening MRI in specific patient populations is discussed in order to give clinicians the information they need to confidently and appropriately utilize breast MRI as an adjunct to screening mammography.

Keywords

Breast imaging, Breast MRI, Breast cancer screening, Screening guidelines

Introduction

The utility of MRI in the evaluation of the breast was significantly limited until an evolution occurred in the 1980s. First, El Yousef et al. suggested in their study in 1985 that MRI may have a role as an adjunct to mammography screening, as MRI showed higher signal intensity for breast carcinoma than normal duct tissue [1]. However, differentiating benign from malignant disease was still limited until gadolinium-based contrast was introduced. Contrast enhancement in cancer correlates with increased vascularity and permeability exhibited in the neoplasm. The efficacy of MRI with contrast enhancement in the detection of breast cancer was first reported by Heywang et al. in 1986. They examined gadolinium enhanced breast MRIs in 20 patients with breast cancer. In these twenty patients, MRI with gadolinium showed enhancement of all breast cancers in contrast with normal breast tissue and yielded additional diagnostic information in 4 of the 20 patients when compared to mammogram or MRI without gadolinium [2]. This ushered in a new tool for the detection and further evaluation of breast cancer. Studies evaluating dynamic enhancement kinetics followed and demonstrated further diagnostic value in differentiating benign from malignant breast lesions [3-6].

Body

Breast MRI was approved by the FDA as an adjunct to mammography in the detection of breast cancer in 1991. In the intervening decades, breast MRI has been further refined and is now the most sensitive imaging tool available in the diagnosis of invasive breast cancer. There are limitations, however, and these must be weighed against the potential benefits [7]. In this perspective review, we will examine evidence-based recommendations for breast MRI as a screening tool.

To aid clinicians in deciding when to order a screening breast MRI in their patients by weighing the potential benefits with limitations inherent in MRI, the American Cancer Society (ACS) released guidelines in 2007. These guidelines, based on evidence and/or expert opinion, recommend screening breast MRI in patients with a BRCA mutation, 1° degree relatives of patients with a BRCA mutation, lifetime risk of breast cancer 20-25% or greater based on risk models, history of radiation to the chest age 10-30, Li Fraumeni syndrome and 1° degree relatives, and Cowden and Bannayan-Riley-Ruvalcaba syndromes and first degree relatives. The recommendations also mention instances when MRI screening can be considered, but where there is insufficient evidence to support or recommend against MRI screening. These include patients with lifetime risk of 15-20%, history of Lobular Carcinoma in Situ (LCIS), Atypical Lobular Hyperplasia (ALH), or Atypical Ductal Hyperplasia (ADH), mammographically dense breasts, and personal history of breast cancer. They recommend against screening in patients with less than 15% lifetime risk of breast cancer [8].

In their most recent revision of appropriateness criteria for breast MRI screening, the American College of Radiology states that they and the Society of Breast Imaging endorse the ACS recommendations. They also stress screening breast MRI should not be used as a substitute for screening mammography, but rather as an adjunct (accessed 2016). Guidelines released by the National Comprehensive Cancer Network (NCCN) in 2009 recommend considering breast MRI screening as an adjunct to mammography in patients with BRCA1 or BRCA2 mutations, patients with lifetime risk of breast cancer > 20% based on risk models highly dependent on family history, patients with a history of chest radiation between ages 10 and 30, certain genetic mutation carriers (TP53 or PTEN genes), and for patients with a history of LCIS [9]. It is important to note the NCCN stresses risk assessment based on models highly dependent on family history, which would exclude the Gail model due to this limitation [10]. In the United Kingdom, the National Institute for Health and Care Excellence (NICE) offers recommendations for breast MRI screening in patients with breast cancer family history,
and it gives recommendations broken down by age group. These guidelines recommend annual MRI screening beginning at age 20 for patients with high probability of TP53 mutation and beginning at age 30 for patients with BRCA1 or BRCA2 mutations, for instance [11].

The evidence behind these recommendations for breast MRI screening continues to evolve. A number of studies have shown benefit in high risk (> 20% lifetime risk) women or genetic mutation carriers [12-18]. A meta-analysis by Warner et al. in 2008 examined 11 prospective, non-randomized studies where MRI with mammography was compared with mammography alone in annual screening of women at high genetic risk for breast cancer. The meta-analysis yielded an increase in sensitivity for the detection of breast cancer of 94% when combined with mammography compared to just mammography alone. The specificity ranges for the studies were 25-59% for mammography alone vs. 80-100% when combined with MRI [19]. This is similar to other studies, including the prospective multicenter trial by Sardenelli et al. comparing clinical breast examination, mammography, ultrasonography, and contrast enhanced MRI in surveillance of asymptomatic high risk women. The authors found MRI was more sensitive (91%) than clinical breast examination (18%), mammography (50%), ultrasonography (52%), or mammography plus ultrasonography (63%). In this study, 31% of cancers were detected only by MRI. This did come at the cost of decreased specificity when MRI was added to mammography, of 96% vs. 99% for mammography alone [16]. This is similar to the 95% specificity of mammography and MRI vs. 99% specificity of mammography alone in the overall meta-analysis by Warner and colleagues. In all but one of the studies analyzed, the specificity of MRI with mammography was lower than mammography alone (range 73-93% vs. 91-100%) [19]. Of note, the study by sardenilla and colleagues also showed no added benefit of adding ultrasound screening in patients screened with mammogram and MRI [16]. The study by Riedl and colleagues in 2015 examining high risk screening with mammography, sonography, and MRI showed an even higher percentage of cancers detected by MRI alone at 45% vs. 5% by mammography alone and 0% detected by ultrasound alone [17].

Additional studies since the ACS released their guidelines in 2007 lend further evidence to the subset of instances where insufficient data were present to recommend for or against MRI screening. MRI screening demonstrated benefit in patients with atypia or LCIS with added cancer detection rates (ACDR) of 2-4% for cancers detected by MRI alone [20-22]. This is in line with numbers from other studies for patients at high lifetime risk. For instance, the study by Riedl et al. noted above found an added cancer detection rate of 1.3% for MRI alone translating into an additional 13 cancers detected per 1000 screening MRIs performed. Again, these added cancers detected are at the expense of additional biopsies or imaging, as reflected in the lower specificity for MRI. Schwartz and colleagues suggested in their conclusion that the PPV of 20% and the increased callback rate of 24% may not justify MRI screening in their population for the 2% ACDR [22]. In contrast, Friedlander and colleagues recommended MRI screening in their population of patients with history of LCIS as their 4% ACDR was in line with other studies of breast MRI in high risk patient populations [21]. As the evidence is still limited, additional studies will help strengthen a recommendation for or against MRI screening in patients with a history of atypia and LCIS.

In patients with a personal history of breast cancer and no other risk factors, Brennan and colleagues did a retrospective study of 1699 screening MRIs. They found a cancer detection rate of 12% where 59% were detected by MRI alone. MRI in this study yielded a PPV of 39%. Results of this study suggest a definite benefit in this population. It is important to note, a high biopsy rate was seen in this population during the study. Thirty percent (44/144) of the patients with a history of breast cancer in their screening regimen underwent biopsy to detect cancer in 17/44 biopsies [23].

Data are limited in evaluating screening MRI for patients with dense breasts. Dutch researchers have launched the Dense Tissue and Early Breast Neoplasm Screening (DENSE) trial to evaluate the cost and effectiveness of MRI screening in patients with negative mammograms and dense breasts. The trial is currently ongoing. At this time, implementation of breast MRI screening in patients with dense breasts is not supported by sufficient data [24].

While a number of studies have shown improved cancer detection with the addition of breast MRI to the screening regimen, as noted in studies above, evidence of survival improvement is limited to date. A survival analysis of breast MRI screening in high-risk women by Evans and colleagues from the MARIBS (magnetic resonance imaging breast screening) study in 2014 showed a 95% 10 year survival rate for the MRI + mammography screening group compared to 88% for the mammography alone group. This result, however, was not statistically significant. In a study by Evans and colleagues in 2016 of intensive breast screening of BRCA2 mutation carriers, patients with combined MRI + mammography had a 10 year survival of 100% compared to 86% in the mammography alone group [25]. Thus, survival benefit for breast MRI screening vs. mammography alone is an active area of investigation.

Benefits of MRI screening should be weighed against limitations inherent in MRI exams. One important limitation is increased cost compared to mammography alone. Saadatmand and colleagues evaluated data from a large prospective MRI screening study in patients with familial risk factors and estimated lifetime risk of breast cancer > 15%. They found that adding MRI to the screening regimen yearly was 2.5 times more expensive per life year gained. The benefit of this increased cost in their study was an estimated mortality reduction of 25% vs. 17% with mammography and clinical breast exam screening without MRI [26].

Another limitation of MRI noted earlier is decreased specificity in lesion evaluation with MRI screening. For instance, in a study by Raikihin and colleagues, they report specificity of 86% for breast MRI with associated callback rates at nearly 10 times higher. This came, however, with the added benefit of detecting an additional 10 cancers per 1000 patients screened with MRI and mammography vs. mammography alone [27]. These data are in line with the studies noted previously regarding specificity. It is also important to note, in comparing MRI to screening ultrasound, many studies have shown the specificity of MRI to be higher [9]. Finally, limitations in sensitivity should be mentioned, where false negative MR exams have been shown to be associated more commonly with DCIS [28]. However, later studies using higher resolution images have shown higher sensitivity for detecting DCIS than mammography [9,12,29].

Addressing the cost and acquisition time limitations, active research in abbreviated protocol screening breast MRI shows promising results. In 2014, Kuhl and colleagues conducted a prospective observational reader study on an abbreviated breast MRI based on maximum intensity projection analysis of the early postcontrast T1 images (see example Figure 1D). Compared with the full protocol with an acquisition time of 17 minutes, the abbreviated protocol took 3 minutes to acquire with an average 28 seconds to read. Additionally, the abbreviated protocol showed equivalent diagnostic accuracy [30]. Since then, additional studies lend further evidence that the abbreviated screening protocols may replace the full protocols in the future without sacrificing diagnostic accuracy [31-33].

Conclusion

In summary, breast MRI demonstrates both benefits and limitations in the detection of breast cancer when added to a screening regimen. Studies to date demonstrate in patients with estimated lifetime risk of breast cancer > 20%, benefits typically outweigh limitations. Data on survival benefits are limited, though recent studies suggest a trend toward improved survival outcomes for high-risk patients. On the other hand, in patients with lifetime risk < 15%, the limitations such as cost and decreased specificity may not justify the increase in sensitivity. New data suggest benefits may

References

Figure 1: The CC (1A) and MLO (1B) mammogram of the left breast in a patient with personal history of breast cancer were read as normal. Subsequent breast MRI performed for history of breast cancer (1C, T1 post-contrast with fat subtraction and 1D, T1 post-contrast with fat subtraction and dynamic subtraction maximum intensity projection) showed a 6 mm mass in the left breast at the 2:00 position (yellow arrows) which was mammographically occult. Second look ultrasound (1E) showed a corresponding irregular hypoechoic mass. Subsequent ultrasound-guided biopsy yielded Invasive Ductal Carcinoma grade 2.


